Is A Late Stage Ovarian Cancer Patient Alive 19 Years Later Because Of Serendipity

A late stage German ovarian cancer patient, who was given months to live, in 1987 was injected with a then-experimental bio tech drug. The monoclonal antibody was being used to track tumors in the ovarian cancer patients body. Instead, it may lead to a breakthrough treatment for ovarian cancer patients. End Quote

(1888PressRelease) March 28, 2006 - In a recent internet news website article, University of Alberta Professor Emeritus Antoine Noujaim told StockInterview.com, “There is the very original (ovarian cancer) patient who was injected in 1987. She’s in Germany, and according to Dr. Baum she was still alive a year ago.” Over 500 patients were injected with the murine monoclonal antibody, which Dr. Antoine Noujaim pioneered during early clinical trials, to determine the ovarian cancer drug’s efficacy. The ovarian cancer drug came about by accident when Dr. Baum, a researcher in Germany noticed an improvement in late stage ovarian cancer patients. He was using the “B43.13 antibody,” which Dr. Noujaim had developed for imaging tumors in women with late stage ovarian cancer. Dr. Baum became puzzled when they were not dying on schedule, and notified Dr. Noujaim who began his two-decade long quest to commercialize the discovery.

As a result of this nearly twenty-year old scientific accident, one such German patient may very well be alive today. According to Dr. Noujaim, who told StockInterview.com, “It’s a matter of great pride for me that some people who received OvaRex® MAb are alive today.” The murine monoclonal antibody is reportedly designed to help the patient’s immune system recognize and more effectively fight ovarian cancer. Previous clinical studies showed an ‘average time to relapse’ of 14 months.

Phase III clinical trials for OvaRex® MAb are currently being conducted in about 64 research centers across the United States through Unither Pharmaceuticals, a wholly owned subsidiary of United Therapeutics (NASDAQ NM: UTHR), which has licensed OvaRex® MAb, from ViRexx Medical Corp (Amex: REX; Toronto: VIR).

The interview with OvaRex® MAb inventor, Dr. Antoine Noujaim can be found on the internet news website, StockInterview.com:
http://www.stockinterview.com/virexx.html

###

Visit ArtJen Complexus Holdings Corp. Website

space